Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Elekta's Flexitron brachytherapy afterloading platform approved in China

Elekta's Flexitron brachytherapy afterloading platform approved in China

Elekta announces that the China Food and Drug Administration has approved Elekta's Flexitron brachytherapy afterloading platform for sale and marketing in China. [More]
Tel Aviv University study throws spotlight on gene mutation responsible for premature ovarian failure

Tel Aviv University study throws spotlight on gene mutation responsible for premature ovarian failure

Premature ovarian failure, also known as primary ovarian insufficiency (POI), affects 1% of all women worldwide. In most cases, the exact cause of the condition, which is often associated with infertility, is difficult to determine. [More]
ASTRO's education programs recognized with ACCME accreditation

ASTRO's education programs recognized with ACCME accreditation

The American Society for Radiation Oncology's education credentials have been recognized and upgraded by the Accreditation Council for Continuing Medical Education from Accreditation to Accreditation with Commendation, approved at the ACCME's December 2014 meeting. [More]
Two-thirds of U.S. women with early-stage breast cancer receive longer radiation therapy

Two-thirds of U.S. women with early-stage breast cancer receive longer radiation therapy

Two-thirds of women treated for early-stage breast cancer in the U.S. receive longer radiation therapy than necessary, according to a new study published in JAMA this week from Penn Medicine researchers Ezekiel J. Emanuel, MD, PhD, and Justin E. Bekelman, MD. [More]
Using refractory metals in cancer treatments: an interview with Robert Desberg, H.C. Starck

Using refractory metals in cancer treatments: an interview with Robert Desberg, H.C. Starck

By developing and producing customized powder morphologies and high-precision mill products, and fabricated and machined components from the refractory metals tungsten, molybdenum, tantalum, and niobium, H.C. Starck makes a significant contribution to enabling cutting-edge developments in innovative high-tech industries. [More]
Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ≥50 miles away from a cancer center, according to a study published in the December 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology. [More]
Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

In a groundbreaking new study, UCLA researchers have for the first time advanced a surgical technique performed with the help of a robot to successfully access a previously-unreachable area of the head and neck. [More]
Findings open new avenues for research to predict risk of therapy-related AML

Findings open new avenues for research to predict risk of therapy-related AML

For a small percentage of cancer patients, treatment aimed at curing the disease leads to a form of leukemia with a poor prognosis. Conventional thinking goes that chemotherapy and radiation therapy induce a barrage of damaging genetic mutations that kill cancer cells yet inadvertently spur the development of acute myeloid leukemia (AML), a blood cancer. [More]
Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report. [More]
Baylor-led researchers identify gene linked to familial glioma

Baylor-led researchers identify gene linked to familial glioma

An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease. [More]
Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Researchers identify new targets for future CLL therapies

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so. [More]
ASTRO recognized with three 2014 MarCom Awards

ASTRO recognized with three 2014 MarCom Awards

The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure. [More]
CareCore, MedSolutions complete merger agreement

CareCore, MedSolutions complete merger agreement

CareCore National, LLC and MedSolutions, Inc., two leading providers of Specialty Benefits Management (SBM) services to managed care organizations and risk-bearing provider organizations, today announced the completion of a merger that will help advance the companies' collective commitment to containing healthcare costs and achieving quality medical outcomes. [More]
Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital. [More]
Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects. [More]
Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate studies published in the Nov. 20 issue of the journal Immunity. [More]
Gastric cancer patients who receive chemoradiation after surgery have better survival rates

Gastric cancer patients who receive chemoradiation after surgery have better survival rates

Patients who receive chemotherapy and radiation after surgery for gastric cancer appear to have better survival rates than those who had surgery followed by only chemotherapy, according to results of a look-back study of more than 500 people by Johns Hopkins scientists. [More]
Study finds significant disparities in lung cancer treatment based on race, insurance status

Study finds significant disparities in lung cancer treatment based on race, insurance status

African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology. [More]

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. [More]